BioSpace News Archive

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced its financial results for the fourth quarter and full year ended December 31, 2020 and provided initial 2021 guidance.

Impact Therapeutics announced today that the first patient was recently dosed in the first-in-human Phase 1 clinical study of Wee1 Inhibitor IMP7068 in the United States . This is a Phase 1, open-label, multi-center, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity

Secured multi-year commitments for majority of blood plasma supply and production output Catalyst Capital commits additional funding to support accelerated path to market Builds on momentum following appointment of CEO and completion of Phase III clinical trials for PlasmaCap IG (Intravenous Immunoglobulin or “IVIG”)

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the fourth quarter ended December 31, 2020

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Tom West, President & Chief Executive Officer, and Randy Meier, Executive Vice President & Chief Financial Officer, will participate in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference.

- 2021 financing will be a catalyst to further establish Neurelis as a best-in-class epilepsy company - Funds will enhance growth and commercial penetration of company’s lead orphan drug product, VALTOCO® (diazepam nasal spray), and support pipeline development and expansion - Company also announces appointment of healthcare industry expert Alexander Kwit to its Board of Directors

CiRC Biosciences, Inc., a privately held cell therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for chemically induced photoreceptor-like cells (CiPCs) for the treatment of retinitis pigmentosa

New Data Shows 96% Are Still Managing Revenue Tasks With Spreadsheets, and 71% of Executives Believe Their Industries Could Do a Better Job Optimizing Revenue Activities

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company CEO Dwight Egan will be presenting at the 2nd Annual MarketsandMarkets Infectious Disease Diagnostics and Point-Of-Care Testing Virtual Conference, held March 11-12, 2021.

Novum Medical, Inc., a developer of innovative implants using novel biomaterials that have the potential for broad application in the musculoskeletal market, announced Tom Afzal as its new chief executive officer. The Company also announced that it has completed a financing with existing investors.